New oral ITP medicine could be an option for children

25 March 2024
sobi_large

Biotech firm Swedish Orphan Biovitrum, Sobi (STO: SOBI) has announced positive results from the AVA-PED-301 study, evaluating the efficacy and safety of Doptelet (avatrombopag).

The company is testing Doptelet for the treatment of certain children with immune thrombocytopenia (ITP), an autoimmune disorder characterized by low numbers of platelets, leading to bruising and an increased risk of bleeding.

Sobi is looking to broaden the label for its medicine, which was first approved by the US regulator for certain adults with ITP in 2019.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical